Biotech

Trying to Cure My Cystic Fibrosis

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/11/2026, 16:03:24 UTC.

Briefings

This article describes the history of cystic fibrosis (CF) research and treatments, noting that salt crystals in sweat are a symptom of CFTR gene mutations. It details Vertex Pharmaceuticals' development of drugs like ivacaftor and Trikafta to restore CFTR function, which improved life expectancy from 10 to 40 years. The author, diagnosed in 1992, credits these therapies with survival but acknowledges they only delay death. The text explains the biological mechanism where CFTR mutations cause thick mucus and poor nutrient absorption, leading to chronic lung infections and eventual failure.

Key points

• Salt crystals in sweat are a symptom of CFTR gene mutations, which were identified in 1989 as the cause of cystic fibrosis.
• Vertex Pharmaceuticals developed Trikafta in 2019, a combination of three drugs approved for CF patients with specific mutations.

Context

The article explains that salt crystals in sweat are a symptom of CFTR gene mutations, which were identified in 1989 as the cause of cystic fibrosis. Vertex Pharmaceuticals developed Trikafta in 2019, a combination of three drugs approved for CF patients with specific mutations.

Limitations

The article provides historical context on CF research and drug development but does not supply specific patient data, geographic locations, or clinical trial results. The text relies on the author's personal experience and general biological explanations rather than verified clinical outcomes or longitudinal study data.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/11/2026, 16:18:39 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihfuaejjy2ij5g5kjmauw3xpvzcczbhrrjtemy2f5mf3uidp4sts4